WHO ICTRP trial
Phase II single arm open pilot study to demonstrate the efficacy of midostaurin…
NL-OMON39686 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON39686 |
|---|---|
| Public title | Phase II single arm open pilot study to demonstrate the efficacy of midostaurin in symptom improvement and decrease of mast cell burden in patients with indolent or smoldering systemic mastocytosis |
| Scientific title | Phase II single arm open pilot study to demonstrate the efficacy of midostaurin in symptom improvement and decrease of mast cell burden in patients with indolent or smoldering systemic mastocytosis - Midostaurin in Indolent Systemic Mastocytosis |
| Primary sponsor | Universitair Medisch Centrum Groningen |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | Netherlands |
| Conditions | mastocytosis; mast cell disease;10018865;mastocytosis; mast cell disease |
| Interventions | treatment with Midostaurin, twice daily 100 mg orally for 6 months continuously. ;mast cell;systemic mastocytose;therapy;tyrosine kinase inhibitor |
| Registration date | Feb 7, 2013 |
| Target size | 20 |
| Secondary IDs | 2012-004868-22;NL41973.042.12 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: